Header Logo

Connection

ERNEST HAWK to Humans

Back to Details
This is a "connection" page, showing publications ERNEST HAWK has written about Humans.
ERNEST HAWK
Connection Strength
0.775
Humans
  1. Reducing risk for chronic disease: evaluation of a collective community approach to sustainable evidence-based health programming. BMC Public Health. 2024 01 20; 24(1):240.
    View in: PubMed
    Score: 0.019
  2. Recent American College of Physicians Guidance Statement for Screening Average-risk, Asymptomatic Adults for Colorectal Cancer. Cancer Prev Res (Phila). 2024 01 04; 17(1):1-5.
    View in: PubMed
    Score: 0.019
  3. Be Well? Acres Homes: a community-driven, evidence-based approach to reduce health inequities through sustained cross-sector partnership. Cancer Causes Control. 2024 Apr; 35(4):611-622.
    View in: PubMed
    Score: 0.019
  4. It Doesn't Need to Take 25 Years: Emphasizing Cancer Prevention and Control in President Biden's Cancer Moonshot. JCO Oncol Pract. 2023 10; 19(10):831-834.
    View in: PubMed
    Score: 0.018
  5. Multicancer early detection test: Preclinical, translational, and clinical evidence-generation plan and provocative questions. Cancer. 2022 02 15; 128 Suppl 4:861-874.
    View in: PubMed
    Score: 0.017
  6. A Comprehensive Program to Reduce Tobacco-related Cancers Through Actions by a National Cancer Institute-designated Cancer Center. Cancer Control. 2022 Jan-Dec; 29:10732748221138713.
    View in: PubMed
    Score: 0.016
  7. Be Well Communities?: mobilizing communities to promote wellness and stop cancer before it starts. Cancer Causes Control. 2021 Aug; 32(8):859-870.
    View in: PubMed
    Score: 0.016
  8. The ASPREE Trial: An Unanticipated Stimulus for Greater Precision in Prevention? J Natl Cancer Inst. 2021 03 01; 113(3):221-222.
    View in: PubMed
    Score: 0.015
  9. E-Cigarettes: Unstandardized, Under-Regulated, Understudied, and Unknown Health and Cancer Risks. Cancer Res. 2019 12 15; 79(24):6079-6083.
    View in: PubMed
    Score: 0.014
  10. AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health. Cancer Prev Res (Phila). 2018 12; 11(12):735-778.
    View in: PubMed
    Score: 0.013
  11. NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question. J Natl Cancer Inst. 2018 09 01; 110(9):927-928.
    View in: PubMed
    Score: 0.013
  12. MD Anderson's Population Health Approaches to Cancer Prevention. Tex Med. 2018 02 01; 114(2):34-41.
    View in: PubMed
    Score: 0.012
  13. Cancer Prevention Recommendations: Impact of Adherence. Semin Oncol Nurs. 2016 08; 32(3):306-13.
    View in: PubMed
    Score: 0.011
  14. Ernest Hawk Discusses the NCI-Designated Cancer Centers' Joint Statement on the HPV Vaccine. Oncology (Williston Park). 2016 Jul; 30(7):599-600.
    View in: PubMed
    Score: 0.011
  15. Aspirin for Cancer Prevention: One Step Closer. JAMA Oncol. 2016 Jun 01; 2(6):770-1.
    View in: PubMed
    Score: 0.011
  16. Cancer prevention in developing countries: a vision for preserving health in Mexico. Salud Publica Mex. 2016 Apr; 58(2):93-6.
    View in: PubMed
    Score: 0.011
  17. When "Effective" Prevention Agents Fail to Elicit Anticipated Effects: Challenges in Trial Design. Cancer Prev Res (Phila). 2016 Feb; 9(2):125-7.
    View in: PubMed
    Score: 0.011
  18. Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. Semin Oncol. 2016 Feb; 43(1):65-77.
    View in: PubMed
    Score: 0.011
  19. Molecular cancer prevention: Current status and future directions. CA Cancer J Clin. 2015 Sep-Oct; 65(5):345-83.
    View in: PubMed
    Score: 0.011
  20. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut. 2016 Feb; 65(2):286-95.
    View in: PubMed
    Score: 0.010
  21. Urinary PGE-M in colorectal cancer: predicting more than risk? Cancer Prev Res (Phila). 2014 Oct; 7(10):969-72.
    View in: PubMed
    Score: 0.010
  22. Convergence of nanotechnology and cancer prevention: are we there yet? Cancer Prev Res (Phila). 2014 Oct; 7(10):973-92.
    View in: PubMed
    Score: 0.010
  23. Five National Cancer Institute-designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials: a current view and opportunities for improvement. Cancer. 2014 Apr 01; 120 Suppl 7:1113-21.
    View in: PubMed
    Score: 0.010
  24. AACR celebrates 50 years of tobacco research and policy. Clin Cancer Res. 2014 Apr 01; 20(7):1709-18.
    View in: PubMed
    Score: 0.010
  25. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila). 2013 Mar; 6(3):196-205.
    View in: PubMed
    Score: 0.009
  26. Trials and tribulations of interrogating biomarkers to define efficacy of cancer risk reductive interventions. Cancer Prev Res (Phila). 2013 Feb; 6(2):71-3.
    View in: PubMed
    Score: 0.009
  27. Cancer chemoprevention: successes and failures. Clin Chem. 2013 Jan; 59(1):94-101.
    View in: PubMed
    Score: 0.009
  28. Chemoprevention--history and general principles. Best Pract Res Clin Gastroenterol. 2011 Aug; 25(4-5):445-59.
    View in: PubMed
    Score: 0.008
  29. Conference Report: Eighth Annual AACR International Conference on Frontiers in Cancer Prevention Research. Cancer Prev Res (Phila). 2010 Aug; 3(8):1044-8.
    View in: PubMed
    Score: 0.007
  30. Modelling a dream: the molecular prevention of pancreatic cancer. Gut. 2010 May; 59(5):566-8.
    View in: PubMed
    Score: 0.007
  31. Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res. 2009 Jul 01; 69(13):5269-84.
    View in: PubMed
    Score: 0.007
  32. Improving the vision of colonoscopy: does the fine print really matter? Cancer Prev Res (Phila). 2008 Dec; 1(7):495-8.
    View in: PubMed
    Score: 0.007
  33. The Translational Research Working Group developmental pathway for lifestyle alterations. Clin Cancer Res. 2008 Sep 15; 14(18):5707-13.
    View in: PubMed
    Score: 0.007
  34. The Translational Research Working Group developmental pathways: introduction and overview. Clin Cancer Res. 2008 Sep 15; 14(18):5664-71.
    View in: PubMed
    Score: 0.006
  35. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress. Cancer Epidemiol Biomarkers Prev. 2007 Feb; 16(2):185-7.
    View in: PubMed
    Score: 0.006
  36. What is the future of oncology? National Cancer Institute initiatives to improve research, development, and implementation in cancer prevention and treatment. Semin Oncol. 2006 Dec; 33(6 Suppl 11):S6-9.
    View in: PubMed
    Score: 0.006
  37. Do statins prevent cancer? Nat Clin Pract Oncol. 2006 Sep; 3(9):478-9.
    View in: PubMed
    Score: 0.006
  38. A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol. 2006 Feb; 3(2):101-11.
    View in: PubMed
    Score: 0.005
  39. Statins and cancer--beyond the "one drug, one disease" model. N Engl J Med. 2005 May 26; 352(21):2238-9.
    View in: PubMed
    Score: 0.005
  40. The critical role of risk-benefit assessments in cancer prevention. Cancer Epidemiol Biomarkers Prev. 2005 Feb; 14(2):297-8.
    View in: PubMed
    Score: 0.005
  41. Colorectal cancer prevention. J Clin Oncol. 2005 Jan 10; 23(2):378-91.
    View in: PubMed
    Score: 0.005
  42. Prevention and therapy of colorectal cancer. Med Clin North Am. 2005 Jan; 89(1):85-110, viii.
    View in: PubMed
    Score: 0.005
  43. Can animal models help us select specific compounds for cancer prevention trials? Recent Results Cancer Res. 2005; 166:71-87.
    View in: PubMed
    Score: 0.005
  44. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 2004 Sep-Oct; 24(5B):3177-84.
    View in: PubMed
    Score: 0.005
  45. Colorectal cancer chemoprevention--an overview of the science. Gastroenterology. 2004 May; 126(5):1423-47.
    View in: PubMed
    Score: 0.005
  46. Cyclooxygenase inhibition in cancer prevention and treatment. Expert Opin Pharmacother. 2003 Dec; 4(12):2193-204.
    View in: PubMed
    Score: 0.005
  47. Aspirin: still learning about the wonder drug. Gut. 2003 Nov; 52(11):1535-6.
    View in: PubMed
    Score: 0.005
  48. Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome. Clin Cancer Res. 2023 11 01; 29(21):4361-4372.
    View in: PubMed
    Score: 0.005
  49. Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev. 2023 10 02; 32(10):1338-1347.
    View in: PubMed
    Score: 0.005
  50. Development of COX inhibitors in cancer prevention and therapy. Am J Clin Oncol. 2003 Aug; 26(4):S48-57.
    View in: PubMed
    Score: 0.005
  51. From Premalignant Biology to Precision Interception: Connecting the Dots with a Curated Collection of Invited Articles. Cancer Prev Res (Phila). 2023 07 05; 16(7):365-367.
    View in: PubMed
    Score: 0.005
  52. Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials. Prog Exp Tumor Res. 2003; 37:210-42.
    View in: PubMed
    Score: 0.004
  53. Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention. Cancer Chemother Biol Response Modif. 2003; 21:759-89.
    View in: PubMed
    Score: 0.004
  54. Ten Years of the International Cancer Control Partnership: Promoting National Cancer Control Plans to Shape the Health System Response for Cancer Control. JCO Glob Oncol. 2023 01; 9:e2200232.
    View in: PubMed
    Score: 0.004
  55. Chemoprevention of colorectal cancer: problems, progress, and prospects. Gastroenterol Clin North Am. 2002 Dec; 31(4):971-99.
    View in: PubMed
    Score: 0.004
  56. Vulvar Cancer Incidence in the United States and its Relationship to Human Papillomavirus Vaccinations, 2001-2018. Cancer Prev Res (Phila). 2022 Nov 01; 15(11):777-784.
    View in: PubMed
    Score: 0.004
  57. Development, Implementation, and Evaluation of a Distance Learning and Telementoring Program for Cervical Cancer Prevention in Cameroon. JAMA Netw Open. 2022 11 01; 5(11):e2240801.
    View in: PubMed
    Score: 0.004
  58. Epidemiology and prevention of colorectal cancer. Surg Clin North Am. 2002 Oct; 82(5):905-41.
    View in: PubMed
    Score: 0.004
  59. Colorectal cancer screening for persons at average risk. J Natl Cancer Inst. 2002 Aug 07; 94(15):1126-33.
    View in: PubMed
    Score: 0.004
  60. Gut Microbiome Alterations Associated with Diabetes in Mexican Americans in South Texas. mSystems. 2022 06 28; 7(3):e0003322.
    View in: PubMed
    Score: 0.004
  61. Chemoprevention of colorectal carcinogenesis. Int J Clin Oncol. 2002 Feb; 7(1):2-26.
    View in: PubMed
    Score: 0.004
  62. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des. 2002; 8(12):1035-62.
    View in: PubMed
    Score: 0.004
  63. Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease. Hepatology. 2022 04; 75(4):955-967.
    View in: PubMed
    Score: 0.004
  64. The future of colon cancer prevention. Ann N Y Acad Sci. 2001 Dec; 952:88-108.
    View in: PubMed
    Score: 0.004
  65. Circulating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics. Cancer Epidemiol Biomarkers Prev. 2021 09; 30(9):1643-1651.
    View in: PubMed
    Score: 0.004
  66. Cross-sectional survey for assessing cancer care providers' characteristics and attitudes on smoking cessation in Colombia and Mexico. BMJ Open. 2021 02 01; 11(2):e041447.
    View in: PubMed
    Score: 0.004
  67. Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and research. Ann Intern Med. 2001 Jan 16; 134(2):158-60.
    View in: PubMed
    Score: 0.004
  68. Rethinking Environmental Carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2020 10; 29(10):1870-1875.
    View in: PubMed
    Score: 0.004
  69. The Performance of Colorectal Cancer Screening in Brazil: The First Two Years of the Implementation Program in Barretos Cancer Hospital. Cancer Prev Res (Phila). 2021 02; 14(2):241-252.
    View in: PubMed
    Score: 0.004
  70. Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. BMC Cancer. 2020 Sep 10; 20(1):871.
    View in: PubMed
    Score: 0.004
  71. Primary cancer prevention trials. Hematol Oncol Clin North Am. 2000 Aug; 14(4):809-30.
    View in: PubMed
    Score: 0.004
  72. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev. 2000 May; 9(5):523-7.
    View in: PubMed
    Score: 0.004
  73. Biomarkers as surrogates for cancer development. Curr Oncol Rep. 2000 May; 2(3):242-50.
    View in: PubMed
    Score: 0.004
  74. Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study. Support Care Cancer. 2021 Jan; 29(1):97-105.
    View in: PubMed
    Score: 0.004
  75. Using Continuous Glucose Monitoring to Motivate Physical Activity in Overweight and Obese Adults: A Pilot Study. Cancer Epidemiol Biomarkers Prev. 2020 04; 29(4):761-768.
    View in: PubMed
    Score: 0.004
  76. Chemoprevention in hereditary colorectal cancer syndromes. Cancer. 1999 Dec 01; 86(11 Suppl):2551-63.
    View in: PubMed
    Score: 0.004
  77. Characteristics of us adults attempting tobacco use cessation using e-cigarettes. Addict Behav. 2020 01; 100:106123.
    View in: PubMed
    Score: 0.003
  78. A Pilot Study Evaluating Organochlorine and Organophosphate Pesticide Exposure in Children and Adolescents of Mexican Descent Residing in Hidalgo County, Texas. J Immigr Minor Health. 2019 Aug; 21(4):751-760.
    View in: PubMed
    Score: 0.003
  79. Clinical factors associated with adherence to aerobic and resistance physical activity guidelines among cancer prevention patients and survivors. PLoS One. 2019; 14(8):e0220814.
    View in: PubMed
    Score: 0.003
  80. Mind the Gap: Precision Oncology and Its Potential to Widen Disparities. J Oncol Pract. 2019 06; 15(6):301-304.
    View in: PubMed
    Score: 0.003
  81. Building a health communication brand for University of Texas System tobacco control. J Am Coll Health. 2019 May-Jun; 67(4):291-298.
    View in: PubMed
    Score: 0.003
  82. Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine. 2019 Apr; 42:296-303.
    View in: PubMed
    Score: 0.003
  83. Cancer-Related Risk Perceptions and Beliefs in Texas: Findings from a 2018 Population-Level Survey. Cancer Epidemiol Biomarkers Prev. 2019 03; 28(3):486-494.
    View in: PubMed
    Score: 0.003
  84. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Ann Oncol. 2018 10 01; 29(10):2061-2067.
    View in: PubMed
    Score: 0.003
  85. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev. 2018 09; 37(2-3):439-454.
    View in: PubMed
    Score: 0.003
  86. Perspectives on Strengthening Cancer Research and Control in Latin America Through Partnerships and Diplomacy: Experience of the National Cancer Institute's Center for Global Health. J Glob Oncol. 2018 09; 4:1-11.
    View in: PubMed
    Score: 0.003
  87. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. JAMA Oncol. 2018 08 01; 4(8):1085-1092.
    View in: PubMed
    Score: 0.003
  88. Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev. 2018 07 01; 32(13-14):868-902.
    View in: PubMed
    Score: 0.003
  89. Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer Res. 2017 11 15; 77(22):6119-6130.
    View in: PubMed
    Score: 0.003
  90. Mutational Heterogeneity in APC and KRAS Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis. Clin Cancer Res. 2017 Oct 01; 23(19):5936-5947.
    View in: PubMed
    Score: 0.003
  91. The somatic mutation landscape of premalignant colorectal adenoma. Gut. 2018 07; 67(7):1299-1305.
    View in: PubMed
    Score: 0.003
  92. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2017 Nov; 15(11):1791-1799.
    View in: PubMed
    Score: 0.003
  93. Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Rev. 2017 06; 36(2):199-213.
    View in: PubMed
    Score: 0.003
  94. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev. 2017 06; 36(2):289-303.
    View in: PubMed
    Score: 0.003
  95. Building trust and diversity in patient-centered oncology clinical trials: An integrated model. Clin Trials. 2017 Apr; 14(2):170-179.
    View in: PubMed
    Score: 0.003
  96. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun. 2016 08 30; 7:12601.
    View in: PubMed
    Score: 0.003
  97. Genomic Landscape of Colorectal Mucosa and Adenomas. Cancer Prev Res (Phila). 2016 06; 9(6):417-27.
    View in: PubMed
    Score: 0.003
  98. NSAID trials, sporadic adenomas, and conservative inferences. Gastroenterology. 1996 Feb; 110(2):654-5.
    View in: PubMed
    Score: 0.003
  99. Germline Genetic Variants in the Wnt/?-Catenin Pathway as Predictors of Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2016 Mar; 25(3):540-6.
    View in: PubMed
    Score: 0.003
  100. Cohort Profile: The MD Anderson Cancer Patients and Survivors Cohort (MDA-CPSC). Int J Epidemiol. 2016 06; 45(3):713-713f.
    View in: PubMed
    Score: 0.003
  101. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology. 2015 Jul; 149(1):119-29.
    View in: PubMed
    Score: 0.003
  102. Should CMS cover lung cancer screening for the fully informed patient? JAMA. 2014 Sep 24; 312(12):1193-4.
    View in: PubMed
    Score: 0.002
  103. Strategy for prevention of cancers of the esophagus. Ann N Y Acad Sci. 2014 Sep; 1325:108-26.
    View in: PubMed
    Score: 0.002
  104. Telemedicine and telesurgery in cancer care: inaugural conference at MD Anderson Cancer Center. J Surg Oncol. 2014 Sep; 110(4):353-9.
    View in: PubMed
    Score: 0.002
  105. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis. 2013 Dec; 34(12):2750-6.
    View in: PubMed
    Score: 0.002
  106. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog. 2013 Nov; 52 Suppl 1:E139-47.
    View in: PubMed
    Score: 0.002
  107. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31; 382(9894):769-79.
    View in: PubMed
    Score: 0.002
  108. Adenoma detection in patients undergoing a comprehensive colonoscopy screening. Cancer Med. 2013 Jun; 2(3):391-402.
    View in: PubMed
    Score: 0.002
  109. Proceedings of the Indo-U.S. bilateral workshop on accelerating botanicals/biologics agent development research for cancer chemoprevention, treatment, and survival. Cancer Med. 2013 Feb; 2(1):108-15.
    View in: PubMed
    Score: 0.002
  110. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst. 2012 Oct 17; 104(20):1599-611.
    View in: PubMed
    Score: 0.002
  111. Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. Cancer. 2012 Dec 15; 118(24):6188-98.
    View in: PubMed
    Score: 0.002
  112. Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res. 2012 Jul 15; 18(14):3982-91.
    View in: PubMed
    Score: 0.002
  113. Implementing cancer prevention into clinical practice. J Cancer Educ. 2012 May; 27(2 Suppl):S136-43.
    View in: PubMed
    Score: 0.002
  114. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis. 2012 Jul; 33(7):1327-31.
    View in: PubMed
    Score: 0.002
  115. Intake of red meat and heterocyclic amines, metabolic pathway genes and bladder cancer risk. Int J Cancer. 2012 Oct 15; 131(8):1892-903.
    View in: PubMed
    Score: 0.002
  116. The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo. Clin Ther. 2012 Mar; 34(3):569-79.
    View in: PubMed
    Score: 0.002
  117. Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. Carcinogenesis. 2012 Apr; 33(4):841-7.
    View in: PubMed
    Score: 0.002
  118. The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma. Cancer Prev Res (Phila). 2012 Jan; 5(1):61-72.
    View in: PubMed
    Score: 0.002
  119. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila). 2011 Aug; 4(8):1172-80.
    View in: PubMed
    Score: 0.002
  120. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila). 2011 Nov; 4(11):1728-35.
    View in: PubMed
    Score: 0.002
  121. Correspondence re: E. Hawk, et al., Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the First National Health and Nutrition Examination Survey. Cancer Epidemiol.Biomark. Prev., 9: 523-527, 2000. Cancer Epidemiol Biomarkers Prev. 2001 Apr; 10(4):415-6.
    View in: PubMed
    Score: 0.002
  122. Precancerous lesions of the digestive tract. The 18th Annual Symposium of the European Cancer Prevention Organization. Maastricht, The Netherlands. 12-14 October 2000. Abstracts. Eur J Cancer Prev. 2000 Dec; 9(6):443-63.
    View in: PubMed
    Score: 0.002
  123. Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila). 2010 Sep; 3(9):1176-86.
    View in: PubMed
    Score: 0.002
  124. Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila). 2010 May; 3(5):588-96.
    View in: PubMed
    Score: 0.002
  125. Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer. Cancer Prev Res (Phila). 2010 Apr; 3(4):505-17.
    View in: PubMed
    Score: 0.002
  126. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol. 2010 Jun; 105(6):1437-43.
    View in: PubMed
    Score: 0.002
  127. A multicenter study of prevalence and risk factors for aberrant crypt foci. Clin Gastroenterol Hepatol. 2009 May; 7(5):568-74.
    View in: PubMed
    Score: 0.002
  128. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila). 2009 Apr; 2(4):310-21.
    View in: PubMed
    Score: 0.002
  129. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology. 2009 Jun; 136(7):2127-2136.e1.
    View in: PubMed
    Score: 0.002
  130. Cancer epidemiology, biomarkers & prevention, and cancer prevention research: two journals, a common goal. Cancer Epidemiol Biomarkers Prev. 2008 Nov; 17(11):2903-5.
    View in: PubMed
    Score: 0.002
  131. Cancer epidemiology, biomarkers & prevention and cancer prevention research: two journals, a common goal. Cancer Prev Res (Phila). 2008 Nov; 1(6):393-5.
    View in: PubMed
    Score: 0.002
  132. Translational Research Working Group developmental pathway for biospecimen-based assessment modalities. Clin Cancer Res. 2008 Sep 15; 14(18):5672-7.
    View in: PubMed
    Score: 0.002
  133. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila). 2008 Jun; 1(1):32-8.
    View in: PubMed
    Score: 0.002
  134. Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila). 2008 Jun; 1(1):21-31.
    View in: PubMed
    Score: 0.002
  135. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008 Apr 22; 117(16):2104-13.
    View in: PubMed
    Score: 0.002
  136. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007 Apr 04; 99(7):545-57.
    View in: PubMed
    Score: 0.001
  137. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007; 3(1):1-33.
    View in: PubMed
    Score: 0.001
  138. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006 Sep 05; 114(10):1028-35.
    View in: PubMed
    Score: 0.001
  139. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006 Aug 31; 355(9):873-84.
    View in: PubMed
    Score: 0.001
  140. Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population. Cancer Res. 2006 Jul 01; 66(13):6851-60.
    View in: PubMed
    Score: 0.001
  141. Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol Biomarkers Prev. 2006 Jul; 15(7):1382-91.
    View in: PubMed
    Score: 0.001
  142. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006 Jun 15; 12(12):3661-97.
    View in: PubMed
    Score: 0.001
  143. Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev. 2006 May; 15(5):1046-7.
    View in: PubMed
    Score: 0.001
  144. Statins and cancer prevention. Nat Rev Cancer. 2005 Dec; 5(12):930-42.
    View in: PubMed
    Score: 0.001
  145. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology. 2005 Sep; 129(3):863-73.
    View in: PubMed
    Score: 0.001
  146. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar 17; 352(11):1071-80.
    View in: PubMed
    Score: 0.001
  147. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res. 2004 Oct 01; 10(19):6502-11.
    View in: PubMed
    Score: 0.001
  148. Cancer prevention and the American Society of Clinical Oncology. J Clin Oncol. 2004 Oct 01; 22(19):3848-51.
    View in: PubMed
    Score: 0.001
  149. Irreversible ototoxicity associated with difluoromethylornithine. Cancer Epidemiol Biomarkers Prev. 2004 Jul; 13(7):1250-2.
    View in: PubMed
    Score: 0.001
  150. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev. 2004 Jun; 13(6):920-7.
    View in: PubMed
    Score: 0.001
  151. Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res. 2004 Apr 15; 64(8):2904-9.
    View in: PubMed
    Score: 0.001
  152. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004 Feb 18; 96(4):261-8.
    View in: PubMed
    Score: 0.001
  153. Testing guidelines for hereditary non-polyposis colorectal cancer. Nat Rev Cancer. 2004 02; 4(2):153-8.
    View in: PubMed
    Score: 0.001
  154. Frontiers in cancer prevention research. Cancer Res. 2003 Sep 15; 63(18):5649-55.
    View in: PubMed
    Score: 0.001
  155. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev. 2003 Aug; 12(8):755-62.
    View in: PubMed
    Score: 0.001
  156. Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev. 2003 Jul; 12(7):593-6.
    View in: PubMed
    Score: 0.001
  157. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res. 2003 Feb-Mar; 523-524:137-44.
    View in: PubMed
    Score: 0.001
  158. Chemoprevention for Barrett's esophagus trial. Design and outcome measures. Dis Esophagus. 2003; 16(3):177-86.
    View in: PubMed
    Score: 0.001
  159. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst. 2002 Jul 03; 94(13):1001-9.
    View in: PubMed
    Score: 0.001
  160. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002 Jun; 50(6):857-60.
    View in: PubMed
    Score: 0.001
  161. Oltipraz concentrations in plasma, buccal mucosa cells, and lipids: pharmacological studies. Cancer Epidemiol Biomarkers Prev. 2001 Mar; 10(3):201-7.
    View in: PubMed
    Score: 0.001
  162. Secondary chemoprevention of upper aerodigestive tract tumors. Semin Oncol. 2001 Feb; 28(1):106-20.
    View in: PubMed
    Score: 0.001
  163. Potential use of lipoxygenase inhibitors for cancer chemoprevention. Expert Opin Investig Drugs. 2000 Sep; 9(9):2121-38.
    View in: PubMed
    Score: 0.001
  164. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000 Jun 29; 342(26):1946-52.
    View in: PubMed
    Score: 0.001
  165. Adenocarcinoma of the esophagus: risk factors and prevention. Oncology (Williston Park). 2000 Apr; 14(4):507-14; discussion 518-20, 522-3.
    View in: PubMed
    Score: 0.001
  166. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2000 Feb; 9(2):127-37.
    View in: PubMed
    Score: 0.001
  167. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr. 2000 02; 130(2S Suppl):467S-471S.
    View in: PubMed
    Score: 0.001
  168. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res. 2000 Jan; 6(1):78-89.
    View in: PubMed
    Score: 0.001
  169. National Cancer Institute--supported cancer chemoprevention research: coming of age. J Clin Oncol. 1999 Nov; 17(11 Suppl):53-62.
    View in: PubMed
    Score: 0.001
  170. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1999 May; 8(5):467-83.
    View in: PubMed
    Score: 0.001
  171. Sex-related differences in bronchial epithelial changes associated with tobacco smoking. J Natl Cancer Inst. 1999 Apr 21; 91(8):691-6.
    View in: PubMed
    Score: 0.001
  172. Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis. 1999 Feb; 20(2):185-91.
    View in: PubMed
    Score: 0.001
  173. Progress in cancer chemoprevention. Ann N Y Acad Sci. 1999; 889:1-13.
    View in: PubMed
    Score: 0.001
  174. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol. 1999; 470:45-53.
    View in: PubMed
    Score: 0.001
  175. Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring. Clin Chem. 1998 Feb; 44(2):420-7.
    View in: PubMed
    Score: 0.001
  176. Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1998 Jan; 7(1):65-78.
    View in: PubMed
    Score: 0.001
  177. Progress in clinical chemoprevention. Semin Oncol. 1997 Apr; 24(2):241-52.
    View in: PubMed
    Score: 0.001
  178. Perspectives and progress in development of breast cancer chemopreventive drugs. Prog Clin Biol Res. 1997; 396:159-83.
    View in: PubMed
    Score: 0.001
  179. Perspectives on chemoprevention agent selection and short-term clinical prevention trials. Eur J Cancer Prev. 1996 Dec; 5 Suppl 2:79-85.
    View in: PubMed
    Score: 0.001
  180. Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology (Williston Park). 1996 Oct; 10(10):1471-84; discussion 1484-8.
    View in: PubMed
    Score: 0.001
  181. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis. 1996 Jul; 17(7):1435-8.
    View in: PubMed
    Score: 0.001
  182. Mechanistic considerations in the evaluation of chemopreventive data. IARC Sci Publ. 1996; (139):203-19.
    View in: PubMed
    Score: 0.001
  183. Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem Suppl. 1996; 25:1-14.
    View in: PubMed
    Score: 0.001
  184. New agents for cancer chemoprevention. J Cell Biochem Suppl. 1996; 26:1-28.
    View in: PubMed
    Score: 0.001
  185. Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem Suppl. 1996; 26:54-71.
    View in: PubMed
    Score: 0.001
  186. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. J Cell Biochem Suppl. 1995; 23:1-9.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.